208 related articles for article (PubMed ID: 8878617)
21. [Activity of trovafloxacin and ten other antimicrobials against gram negative anaerobic bacilli].
Chávez M; García López JL; Coronilla J; Bernal S; Valverde A; Martín Mazuelos E
Rev Esp Quimioter; 1998 Dec; 11(4):349-52. PubMed ID: 9990149
[TBL] [Abstract][Full Text] [Related]
22. Susceptibility of 497 clinical isolates of gram-negative anaerobes to trovafloxacin and eight other antibiotics.
Rotimi VO; Mokaddas EM; Jamal WY; Khodakhast FB; Verghese TL; Sanyal SC
J Chemother; 1999 Oct; 11(5):349-56. PubMed ID: 10632380
[TBL] [Abstract][Full Text] [Related]
23. Methods of measuring susceptibility of anaerobic bacteria to trovafloxacin, including quality control parameters.
Barry AL; Fuchs PC; Thornsberry C; McLaughlin JC; Jenkins SG; Hardy DJ; Allen SD
Eur J Clin Microbiol Infect Dis; 1996 Aug; 15(8):676-8. PubMed ID: 8894579
[TBL] [Abstract][Full Text] [Related]
24. In vitro activity of gemifloxacin compared to seven other oral antimicrobial agents against aerobic and anaerobic pathogens isolated from antral sinus puncture specimens from patients with sinusitis.
Goldstein EJ; Conrads G; Citron DM; Merriam CV; Warren Y; Tyrrell K
Diagn Microbiol Infect Dis; 2002 Feb; 42(2):113-8. PubMed ID: 11858906
[TBL] [Abstract][Full Text] [Related]
25. PCR-based detection of resistance genes in anaerobic bacteria isolated from intra-abdominal infections.
Tran CM; Tanaka K; Watanabe K
J Infect Chemother; 2013 Apr; 19(2):279-90. PubMed ID: 23338012
[TBL] [Abstract][Full Text] [Related]
26. In vitro activity of telithromycin (HMR 3647) against 502 strains of anaerobic bacteria.
Wexler HM; Molitoris E; Molitoris D; Finegold SM
J Antimicrob Chemother; 2001 Apr; 47(4):467-9. PubMed ID: 11266423
[TBL] [Abstract][Full Text] [Related]
27. Activities of garenoxacin (BMS-284756) and other agents against anaerobic clinical isolates.
Hecht DW; Osmolski JR
Antimicrob Agents Chemother; 2003 Mar; 47(3):910-6. PubMed ID: 12604521
[TBL] [Abstract][Full Text] [Related]
28. Susceptibility of anaerobic bacteria to PD 131628.
Nord CE; Hagelbäck A
Eur J Clin Microbiol Infect Dis; 1992 Jan; 11(1):68-71. PubMed ID: 1314176
[TBL] [Abstract][Full Text] [Related]
29. In vitro activity of BAY 12-8039, a new fluoroquinolone.
Woodcock JM; Andrews JM; Boswell FJ; Brenwald NP; Wise R
Antimicrob Agents Chemother; 1997 Jan; 41(1):101-6. PubMed ID: 8980763
[TBL] [Abstract][Full Text] [Related]
30. [Bactericidal activity of Trovafloxacin and Moxifloxacin against Gram-negative anaerobic bacilli].
Bosnea D; Stadoleanu C; Boswell FJ; Buiuc D
Rev Med Chir Soc Med Nat Iasi; 2000; 104(4):117-22. PubMed ID: 12089939
[TBL] [Abstract][Full Text] [Related]
31.
Goldstein EJC; Merriam CV; Citron DM
Antimicrob Agents Chemother; 2020 Aug; 64(9):. PubMed ID: 32631819
[TBL] [Abstract][Full Text] [Related]
32. In vitro activity of telithromycin (HMR 3647) and seven other antimicrobial agents against anaerobic bacteria.
Ackermann G; Schaumann R; Pless B; Claros MC; Rodloff AC
J Antimicrob Chemother; 2000 Jul; 46(1):115-9. PubMed ID: 10882699
[TBL] [Abstract][Full Text] [Related]
33. Comparative activity of ciprofloxacin, ofloxacin, sparfloxacin, temafloxacin, CI-960, CI-990, and WIN 57273 against anaerobic bacteria.
Goldstein EJ; Citron DM
Antimicrob Agents Chemother; 1992 May; 36(5):1158-62. PubMed ID: 1324640
[TBL] [Abstract][Full Text] [Related]
34. Comparative in vitro activities of gemifloxacin, other quinolones, and nonquinolone antimicrobials against obligately anaerobic bacteria.
Kleinkauf N; Ackermann G; Schaumann R; Rodloff AC
Antimicrob Agents Chemother; 2001 Jun; 45(6):1896-9. PubMed ID: 11353648
[TBL] [Abstract][Full Text] [Related]
35. Trovafloxacin compared with levofloxacin, ofloxacin, ciprofloxacin, azithromycin and clarithromycin against unusual aerobic and anaerobic human and animal bite-wound pathogens.
Goldstein EJ; Citron DM; Hudspeth M; Hunt Gerardo S; Merriam CV
J Antimicrob Chemother; 1998 Mar; 41(3):391-6. PubMed ID: 9578167
[TBL] [Abstract][Full Text] [Related]
36. In vitro activity of trovafloxacin against Bacteroides fragilis in mixed culture with either Escherichia coli or a vancomycin- resistant strain of Enterococcus faecium determined by an anaerobic time-kill technique.
Stearne LE; Kooi C; Goessens WH; Bakker-Woudenberg IA; Gyssens IC
Antimicrob Agents Chemother; 2001 Jan; 45(1):243-51. PubMed ID: 11120973
[TBL] [Abstract][Full Text] [Related]
37. In vitro susceptibility of anaerobes to quinolones in the United States.
Hecht DW; Wexler HM
Clin Infect Dis; 1996 Dec; 23 Suppl 1():S2-8. PubMed ID: 8953099
[TBL] [Abstract][Full Text] [Related]
38. Activity of WY-49605 compared with those of amoxicillin, amoxicillin-clavulanate, imipenem, ciprofloxacin, cefaclor, cefpodoxime, cefuroxime, clindamycin, and metronidazole against 384 anaerobic bacteria.
Spangler SK; Jacobs MR; Appelbaum PC
Antimicrob Agents Chemother; 1994 Nov; 38(11):2599-604. PubMed ID: 7872754
[TBL] [Abstract][Full Text] [Related]
39. Susceptibility of anaerobic bacteria to tosufloxacin.
Nord CE; Lindmark A; Persson I; Runow C
Eur J Clin Microbiol Infect Dis; 1992 Mar; 11(3):263-5. PubMed ID: 1597207
[TBL] [Abstract][Full Text] [Related]
40. Susceptibility of anaerobic bacteria in Auckland: 1991-1996.
Shore KP; Pottumarthy S; Morris AJ
N Z Med J; 1999 Nov; 112(1099):424-6. PubMed ID: 10678225
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
